The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.

Palakurthi, Sangeetha; Kuraguchi, Mari; Zacharek, Sima J; Zudaire, Enrique; Huang, Wei; Bonal, Dennis M; Liu, Jeffrey; Dhaneshwar, Abha; DePeaux, Kristin; Gowaski, Martha R; Bailey, Dyane; Regan, Samuel N; Ivanova, Elena; Ferrante, Catherine; English, Jessie M; Khosla, Aditya; Beck, Andrew H; Rytlewski, Julie A; Sanders, Catherine; Laquerre, Sylvie; Bittinger, Mark A; Kirschmeier, Paul T; Packman, Kathryn; Janne, Pasi A; Moy, Christopher; Wong, Kwok-Kin; Verona, Raluca I; Lorenzi, Matthew V

Palakurthi, Sangeetha; Kuraguchi, Mari; Zacharek, Sima J; Zudaire, Enrique; Huang, Wei; Bonal, Dennis M; Liu, Jeffrey; Dhaneshwar, Abha; DePeaux, Kristin; Gowaski, Martha R; Bailey, Dyane; Regan, Samuel N; Ivanova, Elena; Ferrante, Catherine; English, Jessie M; Khosla, Aditya; Beck, Andrew H; Rytlewski, Julie A; Sanders, Catherine; Laquerre, Sylvie; Bittinger, Mark A; Kirschmeier, Paul T; Packman, Kathryn; Janne, Pasi A; Moy, Christopher; Wong, Kwok-Kin; Verona, Raluca I; Lorenzi, Matthew V.

Afiliação

Palakurthi S; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kuraguchi M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Zacharek SJ; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Zudaire E; Janssen, Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania.
Huang W; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Bonal DM; Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, Massachusetts.
Liu J; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Dhaneshwar A; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
DePeaux K; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Gowaski MR; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Bailey D; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Regan SN; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Ivanova E; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Ferrante C; Janssen, Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania.
English JM; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Khosla A; PathAI, Boston, Massachusetts.
Beck AH; PathAI, Boston, Massachusetts.
Rytlewski JA; Adaptive Biotechnologies, Seattle, Washington.
Sanders C; Adaptive Biotechnologies, Seattle, Washington.
Laquerre S; Janssen, Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania.
Bittinger MA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kirschmeier PT; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Packman K; Janssen, Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania.
Janne PA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Moy C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Wong KK; Janssen, Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania.
Verona RI; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Lorenzi MV; Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York University, New York, New York.

Cancer Immunol Res ; 7(9): 1457-1471, 2019 Sep.

Article em En | MEDLINE | ID: mdl-31331945

Assuntos

Antineoplásicos Imunológicos/farmacologia; Imunidade/efeitos dos fármacos; Neoplasias/imunologia; Receptor de Morte Celular Programada 1/antagonistas & inibidores; Receptores de Fatores de Crescimento de Fibroblastos/antagonistas & inibidores; Animais; Biomarcadores; Linhagem Celular Tumoral; Modelos Animais de Doenças; Sinergismo Farmacológico; Humanos; Imunofenotipagem; Linfócitos do Interstício Tumoral/efeitos dos fármacos; Linfócitos do Interstício Tumoral/imunologia; Linfócitos do Interstício Tumoral/metabolismo; Camundongos; Camundongos Transgênicos; Mutação; Neoplasias/tratamento farmacológico; Neoplasias/genética; Neoplasias/metabolismo; Prognóstico; Receptor de Morte Celular Programada 1/genética; Pirazóis/farmacologia; Quinoxalinas/farmacologia; Receptores de Antígenos de Linfócitos T/genética; Receptores de Antígenos de Linfócitos T/metabolismo; Receptores de Fatores de Crescimento de Fibroblastos/genética; Receptores de Fatores de Crescimento de Fibroblastos/metabolismo; Transdução de Sinais/efeitos dos fármacos; Subpopulações de Linfócitos T/efeitos dos fármacos; Subpopulações de Linfócitos T/imunologia; Subpopulações de Linfócitos T/metabolismo; Resultado do Tratamento; Microambiente Tumoral

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Fatores de Crescimento de Fibroblastos / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos / Imunidade / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google